产品
编 号：F745721
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1535963-91-7
产品详情
生物活性：
Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.
体内研究：
Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus.Animal Model:Rattus norvegicus (forty, male, 10-week-old, four equal groups)
Dosage:120 mg
Administration:Subcutaneously, once every 2 weeks, for 4 weeks
Result:Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.
Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.
体内研究：
Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus.Animal Model:Rattus norvegicus (forty, male, 10-week-old, four equal groups)
Dosage:120 mg
Administration:Subcutaneously, once every 2 weeks, for 4 weeks
Result:Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备